Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo in Advanced or Metastatic Soft Tissue Sarcoma
jRCT2080222991Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in soft tissue sarcoma (STS) comparing Doxorubicin + Olaratumab with Doxorubicin + Placebo (2 arms). Started Oct 2015; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCT2080222991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222991.